HomeComparePTKFY vs SBUX

PTKFY vs SBUX: Dividend Comparison 2026

PTKFY yields 4.06% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $116.0K in total portfolio value· pulled ahead in Year 3
10 years
PTKFY
PTKFY
● Live price
4.06%
Share price
$10.88
Annual div
$0.44
5Y div CAGR
19.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.6K
Annual income
$4,502.78
Full PTKFY calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — PTKFY vs SBUX

📍 SBUX pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPTKFYSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PTKFY + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PTKFY pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PTKFY
Annual income on $10K today (after 15% tax)
$345.04/yr
After 10yr DRIP, annual income (after tax)
$3,827.36/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, SBUX beats the other by $52,136.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PTKFY + SBUX for your $10,000?

PTKFY: 50%SBUX: 50%
100% SBUX50/50100% PTKFY
Portfolio after 10yr
$99.5K
Annual income
$35,171.45/yr
Blended yield
35.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

PTKFY
No analyst data
Altman Z
3.3
Piotroski
6/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PTKFY buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPTKFYSBUX
Forward yield4.06%2.75%
Annual dividend / share$0.44$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR19.4%48.3%
Portfolio after 10y$41.6K$157.5K
Annual income after 10y$4,502.78$65,840.13
Total dividends collected$18.1K$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: PTKFY vs SBUX ($10,000, DRIP)

YearPTKFY PortfolioPTKFY Income/yrSBUX PortfolioSBUX Income/yrGap
1$11,185$484.68$11,107$407.21+$78.00PTKFY
2$12,573$604.92$12,512$626.87+$61.00PTKFY
3← crossover$14,211$758.78$14,366$978.69$155.00SBUX
4$16,163$957.09$16,929$1,557.50$766.00SBUX
5$18,509$1,214.69$20,658$2,543.80$2.1KSBUX
6$21,357$1,552.20$26,406$4,302.22$5.0KSBUX
7$24,851$1,998.58$35,877$7,622.00$11.0KSBUX
8$29,185$2,595.01$52,741$14,352.64$23.6KSBUX
9$34,629$3,400.82$85,676$29,243.03$51.0KSBUX
10$41,556$4,502.78$157,513$65,840.13$116.0KSBUX

PTKFY vs SBUX: Complete Analysis 2026

PTKFYStock

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Full PTKFY Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this PTKFY vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PTKFY vs SCHDPTKFY vs JEPIPTKFY vs OPTKFY vs KOPTKFY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.